BMXC Stock Chart & Historical Trading Data $BMXC Updated:

New Post Public Reply Private Reply Replies (0) Message Board
stockcharts
224
BMXC Stock Chart & Historical Trading Data $BMXC Updated: 02-06-2017
Last Trade: 2/6/2017 4:02:00 PM
Last 0.030   +0.009 +42.90%
Open 0.023
Previous Close 0.021
Day High / Low 0.033 / 0.021
Year High / Low 1.520 / 0.040
Volume 29,495,504
Projected Volume 29495504 (101%)
# of Trades / Projected 843 / 843
Dividend / Yield - / -
Abnormal Activity NONE
Abnormal Volume NO
Gap NONE
Candle BULLISH
Volatility Today MEDIUM
Volatility Yesterday LOW
Price Relativity
From 40 Day High 118%
From 80 Day High 5%
From 150 Day High 4%
From 40 Day Low 789%
From 80 Day Low 789%
From 150 Day Low 789%
Pivot Analysis
Price Pivot $ 0.030
Day Resistance 1 $ 0.040
Day Support 1 $ 0.020
Day Resistance 2 $ 0.040
Day Support 2 $ 0.020
Consolidations
Short Term YES
Medium Term YES
Long Term YES
Volume Indicators
20 Day Avg Vol 29,191,320
Today / 20 Day Avg Vol ABOVE
150 Day Avg Vol 7,794,630
Today / 150 Day Avg Vol ABOVE
Abnormal Volume NO
William Volume Accumulation bullish
Volume Price Trend bullish
Momentum Indicators
10 Day Trend bullish
40 Day Trend bearish
100 Day Trend bearish
Stochastics bearish
RSI neutral
MACD bearish
Moving Average Indictors
15 Day Trend bullish
45 Day Trend bearish
100 Day Trend bearish
Mid Term Moving Average Crossover NONE
Long Term Moving Average Crossover NONE
Volatility Indicators
Abnormal Activity Today? NONE
Volatility Index Today MEDIUM
Volatility Index Yesterday LOW
10 Day Volatility DECREASING
20 Day Volatility DECREASING
40 Day Volatility DECREASING

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Protecting Shareholder Rights: iRhythm Technologies Update

Updated Category News Views 104

Understanding Your Rights as a Shareholder For shareholders of iRhythm Technologies, Inc. (NASDAQ: IRTC), it's imperative to be proactive regarding your rights. Engaging with legal experts can significantly empower your ability to affect change and seek justice for any personal or collective grievances stemming from corporate actions. Why Shareholder Action is Crucial...

Continue Reading
Discover the New Credit Risk IQ and its Industry Insights

Updated Category News Views 138

Introducing Credit Risk IQ Credit Benchmark, a leader in delivering essential credit risk data and analytics, has launched an exciting new platform called Credit Risk IQ. This online portal features an extensive library of over 5,000 free monthly reports that explore credit trends at both industry and sector levels. The insights found in these reports are invaluable for...

Continue Reading
9Rooftops Retained as Marketing Agency for South Carolina Tourism

Updated Category News Views 233

9Rooftops Reappointed for South Carolina Tourism Marketing 9Rooftops, known for its innovative marketing strategies, has been reappointed as the Marketing and Advertising Agency of Record for the South Carolina Department of Parks, Recreation & Tourism (SCPRT). This marks a continued partnership aimed at showcasing the beauty and attractions of South Carolina. A...

Continue Reading
Kyivstar Enhances Digital Services with AI Cloud Solutions

Updated Category News Views 203

Kyivstar Revolutionizes Cloud Services with AI Integration Kyivstar Group Ltd (Nasdaq: KYIV; KYIVW) has embarked on an ambitious journey to strengthen digital services within Ukraine. The company has officially announced the integration of groundbreaking artificial intelligence (AI) technologies into its cloud platform, Kyivstar Cloud. This advancement is pivotal for all...

Continue Reading
Akeso Advances Cancer Care with Ivonescimab Phase III Trial Launch

Updated Category News Views 171

Akeso Launches Phase III Trial for Ivonescimab in SCLC Akeso, Inc. (9926.HK) recently announced an exciting milestone in cancer treatment with the first patient being dosed in its Phase III clinical trial. This multicenter, randomized, and double-blind study, named AK112-311/HARMONi-9, evaluates the efficacy and safety of ivonescimab, a unique bispecific antibody that...

Continue Reading